Drug intelligence / Profile preview

TB-UA-1

Development stage: Preclinical
Lead developer: Traverse Biotech
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

TB-UA-1 is an antibody-drug conjugate (ADC) being developed by Traverse Biotech. As of 2024, the drug is in the early stages of development for an undisclosed therapeutic indication. The specific molecular target, antibody component, linker technology, and cytotoxic payload associated with TB-UA-1 have not been publicly revealed by the company. Traverse Biotech focuses on the development of next-generation ADCs, and TB-UA-1 represents one of the proprietary assets in their oncology-focused pipeline.

Beyond the preview

Go deeper on TB-UA-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TB-UA-1.

Explore the full profile